MA47234A - IMMUNOCONJUGATES TARGETING ADAM9 AND THEIR METHODS OF USE - Google Patents
IMMUNOCONJUGATES TARGETING ADAM9 AND THEIR METHODS OF USEInfo
- Publication number
- MA47234A MA47234A MA047234A MA47234A MA47234A MA 47234 A MA47234 A MA 47234A MA 047234 A MA047234 A MA 047234A MA 47234 A MA47234 A MA 47234A MA 47234 A MA47234 A MA 47234A
- Authority
- MA
- Morocco
- Prior art keywords
- adam9
- methods
- immunoconjugates targeting
- immunoconjugates
- targeting
- Prior art date
Links
- 102100024361 Disintegrin and metalloproteinase domain-containing protein 9 Human genes 0.000 title 1
- 101000832769 Homo sapiens Disintegrin and metalloproteinase domain-containing protein 9 Proteins 0.000 title 1
- 229940127121 immunoconjugate Drugs 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662438488P | 2016-12-23 | 2016-12-23 | |
PCT/US2017/067823 WO2018119196A1 (en) | 2016-12-23 | 2017-12-21 | Immunoconjugates targeting adam9 and methods of use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
MA47234A true MA47234A (en) | 2019-10-30 |
MA47234B1 MA47234B1 (en) | 2022-04-29 |
Family
ID=65895715
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA47234A MA47234B1 (en) | 2016-12-23 | 2017-12-21 | Immunoconjugates targeting adam9 and methods of use thereof |
Country Status (2)
Country | Link |
---|---|
AR (1) | AR110428A1 (en) |
MA (1) | MA47234B1 (en) |
-
2017
- 2017-12-21 MA MA47234A patent/MA47234B1/en unknown
- 2017-12-21 AR ARP170103635A patent/AR110428A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
MA47234B1 (en) | 2022-04-29 |
AR110428A1 (en) | 2019-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA45123A (en) | ANTI-TIM-3 ANTIBODIES AND THEIR METHODS OF USE | |
MA50957A (en) | ANTI-TIGIT ANTIBODIES AND THEIR METHODS OF USE | |
MA44955A (en) | ANTI-TAU BODIES AND THEIR METHODS OF USE | |
MA48595A (en) | ANTI-TAU BODIES AND THEIR METHODS OF USE | |
MA43387A (en) | ANTI-GITR ANTIBODIES AND THEIR METHODS OF USE | |
MA46481A (en) | COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED METHODS | |
MA42925A (en) | ANTI-TIGIT ANTIBODIES AND METHODS OF USE | |
MA49288A (en) | SPECIAL OLIGOMERIC REAGENTS AND THEIR METHODS OF USE | |
MA43284A (en) | COMPOUNDS AND THEIR METHODS OF USE | |
MA42302A (en) | BICYCLIC MILKS AND THEIR METHODS OF USE | |
MA42243A (en) | FACTOR XI ANTIBODIES AND METHODS OF USE | |
MA49715A (en) | OLIGOMERS AND CONJUGATES OF OLIGOMERS | |
MA44526A (en) | OXYSTEROLS AND THEIR METHODS OF USE | |
MA43172A (en) | PHARMACEUTICAL COMPOSITIONS AND METHODS OF INHIBITION OF INDOLAMINE 2,3-DIOXYGENASE AND THEIR INDICATIONS | |
DK3142637T3 (en) | KERATIN TREATMENT FORMULATIONS AND METHODS | |
MA43385A (en) | NEW ANTI-CLAUDINE ANTIBODIES AND METHODS OF USE | |
MA42118A (en) | BENZAMIDES SUBSTITUTED AND THEIR METHODS OF USE | |
MA46923A (en) | RNAI-BASED COMPOSITIONS TARGETING THE SERPINA1 GENE AND THEIR METHODS OF USE | |
MA44391A (en) | COMBINATIONS OF ANTI-CD37 IMMUNOCONJUGATES AND ANTI-CD20 ANTIBODIES | |
MA50354A (en) | ANTIBODIES TARGETING CD137 AND THEIR METHODS OF USE | |
MA42685A (en) | SYNTHESIS OF LEVOMETHADONE HYDROCHLORIDE OR DEXTROMETHADONE HYDROCHLORIDE AND THEIR METHODS OF USE | |
HUE058664T2 (en) | Immunoconjugates targeting adam9 and methods of use thereof | |
MA41642A (en) | PROTOXIN II VARIANTS AND METHODS OF USE | |
MA46422A (en) | MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE | |
MA45602A (en) | ANTI-APOC3 ANTIBODIES AND THEIR METHODS OF USE |